Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. This is a really important question. I ...

Cardiac amyloidosis is a serious disease in which abnormal proteins (amyloids) accumulate in the heart muscle and impair heart function. As the disease leads to serious complications such as heart ...

Top line results from a phase 3 trial of vutrisiran (Amvuttra), a new drug from Alnylam for the treatment of transthyretin-mediated amyloidosis with cardiomyopathy, are positive, according to the ...

A patient-administered injection to treat hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) has been recommended for routine NHS use in England. The National Institute for Health and ...

Please provide your email address to receive an email when new articles are posted on . A CRISPR-Cas9-based therapy reduced transthyretin levels in patients with hereditary amyloidosis and ...

MSK cellular therapist Dr. Heather Landau led a phase 1 clinical trial showing CAR T cell therapy is effective against relapsed or resistant AL amyloidosis. “I’ve seen very sick patients have an ...

Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, fatal disease. Vutrisiran, a subcutaneously administered RNA interference therapeutic agent, inhibits the production of ...

One of the most serious complications of rheumatologic and autoimmune diseases can be prevented with biologic drugs, a single-center chart review suggested, and some such products may be more ...

Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis cardiomyopathy, as Alnylam Pharmaceuticals announced expanded FDA approval.

Researchers found that peristaltic pump flow mechanically breaks supersaturation to induce amyloid formation by hen egg white lysozyme, a-synuclein, amyloid b 1-40, and b2-microglobulin. The high ...